Furthermore, we found that in a subgroup of patients with early stage cancer (IA–IIB) (Table 2), and in particular early SCC (Table 3), BCL11A was not only a significant prognostic factor for DFS (HR 0.18, 95% CI 0.05–0.66, P = 0.01), but also for OS (HR 0.17, 95% CI 0.06–0.50, P = 0.001) (Figure 3C-F). This evidence concerns the gene BCL11A and cancer.